Maciej J. Zamek-Gliszczynski, Ph.D. - Publications

Affiliations: 
2006 University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Pharmacology

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Patel M, Taskar KS, Zamek-Gliszczynski MJ. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. Journal of Clinical Pharmacology. 56: S23-S39. PMID 27385177 DOI: 10.1002/jcph.671  0.36
2016 Nunez DJ, Yao X, Lin J, Walker A, Zuo P, Webster L, Krug-Gourley S, Zamek-Gliszczynski MJ, Gillmor DS, Johnson SL. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. Diabetes, Obesity & Metabolism. PMID 26939572 DOI: 10.1111/dom.12656  0.36
2016 Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BK, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ES, Chan EM, Bendell JC. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. European Journal of Cancer (Oxford, England : 1990). 56: 1-9. PMID 26798966 DOI: 10.1016/j.ejca.2015.11.021  0.36
2016 Scheer N, Chu X, Salphati L, Zamek-Gliszczynski MJ. Knockout and humanised animal models to study membrane transporters in drug development Rsc Drug Discovery Series. 2016: 298-332. DOI: 10.1039/9781782623793-00298  0.36
2015 Gray JE, Infante JR, Brail LH, Simon GR, Cooksey JF, Jones SF, Farrington DL, Yeo A, Jackson KA, Chow KH, Zamek-Gliszczynski MJ, Burris HA. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Investigational New Drugs. PMID 26403509 DOI: 10.1007/s10637-015-0278-7  0.36
2015 Xie F, Ke AB, Bowers GD, Zamek-Gliszczynski MJ. Metformin's Intrinsic Blood-to-Plasma Partition Ratio (B/P): Reconciling the Perceived High In Vivo B/P > 10 with the In Vitro Equilibrium Value of Unity. The Journal of Pharmacology and Experimental Therapeutics. 354: 225-9. PMID 26062557 DOI: 10.1124/jpet.115.225698  0.36
2015 Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 490-509. PMID 25587128 DOI: 10.1124/dmd.114.062174  0.36
2015 Peng SB, Zhang X, Paul D, Kays LM, Gough W, Stewart J, Uhlik MT, Chen Q, Hui YH, Zamek-Gliszczynski MJ, Wijsman JA, Credille KM, Yan LZ. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Molecular Cancer Therapeutics. 14: 480-90. PMID 25504752 DOI: 10.1158/1535-7163.MCT-14-0850  0.36
2014 Ware JA, Urquhart BL, Sugiyama Y, Zamek-Gliszczynski MJ. Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how? Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1979-80. PMID 25362071 DOI: 10.1124/dmd.114.060970  0.36
2014 Lee CA, Kalvass JC, Galetin A, Zamek-Gliszczynski MJ. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays. Clinical Pharmacology and Therapeutics. 96: 298-301. PMID 25141954 DOI: 10.1038/clpt.2014.94  0.36
2014 Higgins JW, Ke AB, Zamek-Gliszczynski MJ. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1780-4. PMID 25106415 DOI: 10.1124/dmd.114.058784  0.36
2014 Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clinical Pharmacology and Therapeutics. 95: 473-6. PMID 24747234 DOI: 10.1038/clpt.2014.41  0.36
2014 Zamek-Gliszczynski MJ, Mohutsky MA, Rehmel JL, Ke AB. Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1008-15. PMID 24658455 DOI: 10.1124/dmd.114.057018  0.36
2014 Zamek-Gliszczynski MJ, Chu X, Polli JW, Paine MF, Galetin A. Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 650-64. PMID 24346835 DOI: 10.1124/dmd.113.055558  0.36
2013 Zamek-Gliszczynski MJ, Bao JQ, Day JS, Higgins JW. Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1967-71. PMID 24009308 DOI: 10.1124/dmd.113.053025  0.36
2013 Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, et al. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clinical Pharmacology and Therapeutics. 94: 64-79. PMID 23588311 DOI: 10.1038/clpt.2013.45  0.36
2013 Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, Zamek-Gliszczynski MJ. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clinical Pharmacology and Therapeutics. 94: 80-94. PMID 23588303 DOI: 10.1038/clpt.2013.34  0.36
2013 Zamek-Gliszczynski MJ, Goldstein KM, Paulman A, Baker TK, Ryan TP. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1174-8. PMID 23569176 DOI: 10.1124/dmd.113.051409  0.36
2013 Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ, Cassidy KC. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 714-26. PMID 23305709 DOI: 10.1124/dmd.112.048488  0.36
2012 Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM. Highlights from the international transporter consortium second workshop Clinical Pharmacology and Therapeutics. 92: 553-556. PMID 23085880 DOI: 10.1038/clpt.2012.126  0.36
2012 Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1825-33. PMID 22711747 DOI: 10.1124/dmd.112.046508  0.36
2012 Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1170-7. PMID 22407892 DOI: 10.1124/dmd.112.044875  0.36
2012 Zamek-Gliszczynski MJ, Sprague KE, Espada A, Raub TJ, Morton SM, Manro JR, Molina-Martin M. How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding? Journal of Pharmaceutical Sciences. 101: 1932-40. PMID 22344827 DOI: 10.1002/jps.23081  0.36
2011 Zamek-Gliszczynski MJ, Day JS, Hillgren KM, Phillips DL. Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1794-800. PMID 21708882 DOI: 10.1124/dmd.111.040162  0.36
2011 Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, Chaudhary AK. Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. Journal of Pharmaceutical Sciences. 100: 2498-507. PMID 21213309 DOI: 10.1002/jps.22452  0.36
2010 Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, ... ... Zamek-Gliszczynski MJ, et al. Membrane transporters in drug development. Nature Reviews. Drug Discovery. 9: 215-36. PMID 20190787 DOI: 10.1038/nrd3028  0.36
2009 Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 386-90. PMID 19022942 DOI: 10.1124/dmd.108.023648  0.36
2008 Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Brouwer KL. Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 2156-8. PMID 18719241 DOI: 10.1124/dmd.108.022053  0.36
2008 Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 911-5. PMID 18276836 DOI: 10.1124/dmd.107.019273  0.36
2008 Lee JK, Leslie EM, Zamek-Gliszczynski MJ, Brouwer KL. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicology and Applied Pharmacology. 228: 17-23. PMID 18191164 DOI: 10.1016/j.taap.2007.11.020  0.36
2008 Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, Brouwer KL. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 61-4. PMID 17913796 DOI: 10.1124/dmd.107.017319  0.36
2007 Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrobial Agents and Chemotherapy. 51: 3230-4. PMID 17576841 DOI: 10.1128/AAC.00082-07  0.36
2006 Zamek-Gliszczynski MJ, Nezasa K, Tian X, Bridges AS, Lee K, Belinsky MG, Kruh GD, Brouwer KL. Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-/- and Abcc4-/- mice. The Journal of Pharmacology and Experimental Therapeutics. 319: 1485-91. PMID 16988054 DOI: 10.1124/jpet.106.110106  0.36
2006 Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, Brouwer KL. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Molecular Pharmacology. 70: 2127-33. PMID 16959944 DOI: 10.1124/mol.106.026955  0.36
2006 Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. The Journal of Pharmacology and Experimental Therapeutics. 319: 459-67. PMID 16857726 DOI: 10.1124/jpet.106.101840  0.36
2006 Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 27: 447-86. PMID 16472997 DOI: 10.1016/j.ejps.2005.12.007  0.36
2006 Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 718-23. PMID 16434545 DOI: 10.1124/dmd.105.007922  0.36
2005 Tian X, Zhang P, Zamek-Gliszczynski MJ, Brouwer KL. Knocking down transport: applications of RNA interference in the study of drug transport proteins. Drug Metabolism Reviews. 37: 705-23. PMID 16393889 DOI: 10.1080/03602530500364098  0.36
2005 Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, Brouwer KL. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 1158-65. PMID 15860656 DOI: 10.1124/dmd.104.002188  0.36
2005 Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 287-93. PMID 15528320 DOI: 10.1124/dmd.104.001420  0.36
2005 Kemp DC, Zamek-Gliszczynski MJ, Brouwer KL. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicological Sciences : An Official Journal of the Society of Toxicology. 83: 207-14. PMID 15509663 DOI: 10.1093/toxsci/kfi020  0.36
2004 Ding Q, Gros R, Gray ID, Taussig R, Ferguson SS, Feldman RD. Raf kinase activation of adenylyl cyclases: isoform-selective regulation. Molecular Pharmacology. 66: 921-8. PMID 15385642 DOI: 10.1124/mol.66.4.  0.36
2004 Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. The Journal of Pharmacology and Experimental Therapeutics. 311: 1203-10. PMID 15302892 DOI: 10.1124/jpet.104.070201  0.36
2003 Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ, Stieger B, Brouwer KL. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Molecular Pharmacology. 64: 154-9. PMID 12815171 DOI: 10.1124/mol.64.1.154  0.36
2003 Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL. Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. The Journal of Pharmacology and Experimental Therapeutics. 304: 801-9. PMID 12538836 DOI: 10.1124/jpet.102.044107  0.36
Show low-probability matches.